ListedMainboardPharmaceuticals & DrugsANTHEM

Anthem Biosciences IPO

Anthem Biosciences IPO is a mainboard IPO raising ₹3,395 Cr at ₹540 – ₹570 a share. It listed on 21 Jul 2025 and trades at ₹784 today, +37.5% against its issue price of ₹570. It was subscribed 64× in total.

570
Issue price
784
Price now
+37.5%
Since issue price
21 Jul 2025
Listed on
64×Subscribed (final) · all exchanges

63.9 times more demand than shares on offer

populated partly populated we hold nothing here — the tab says why

How its cohort has done

103 mainboard issues listed in 2025 that we can price today. This is the group this issue belongs to.

+9.1%
Median return since issue price
46.6%
Now trading below their issue price

Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →

How the book finished

The category split is the number worth reading, not the total.

QIB183×
Non-institutional42×
Retail5.64×

QIB: 183× their allocation. Retail: 5.64×.

See the full split, sub-category by sub-category →

What we hold for this issue

Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.

Category split — who bidQIB, non-institutional and retail, with sub-splits
How demand built over timeOnly one reading so far; the series builds as bidding runs
Price-point demand curveLive only — NSE stops serving this once bidding closes
Lead managers and registrar5 banks
Official documents5 documents
Performance since listingComputed from our own daily closes

What happens when

11 Jul 2025Pre-apply opens
14 Jul 2025Bidding opens
16 Jul 2025Bidding closes
18 Jul 2025Allotment finalised — you find out what you got
18 Jul 2025Money refunded to unsuccessful bidders
21 Jul 2025Shares list and start trading
27 Aug 2025UPI mandate expires

Track ANTHEM BIOSCIENCES LTD

Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.

Open the company page

Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.